Serum apelin and galectin-3 in preeclampsia in Iraq

References

• Al-Jameil N, Khan FA, Khan MF, et al. A brief overview of preeclampsia. J Clin Med Res. 2014;6(1):1.
   PubMedGoogle Scholar
• Wu P, Haththotuwa R, Kwok CS, et al. Preeclampsia and future cardiovascular health: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2017;10(2). DOI:10.1161/CIRCOUTCOMES.116.003497.
   PubMed Web of Science ®Google Scholar
• Perucci LO, Corrêa MD, Dusse LM, et al. Resolution of inflammation pathways in preeclampsia—a narrative review. Immunol Res. 2017;65(4):774–789.
   PubMed Web of Science ®Google Scholar
• Galanth C, Hus-Citharel A, Li B, et al. Apelin in the control of body fluid homeostasis and cardiovascular functions. Curr Pharm Des. 2012;18(6):789–798.
   PubMed Web of Science ®Google Scholar
• Li L, Yang G, Li Q, et al. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes. 2006;114(10):544–548.
   PubMed Web of Science ®Google Scholar
• Gilbert JS. From apelin to exercise: emerging therapies for management of hypertension in pregnancy. Hypertens Res. 2017;40(6):519.
   PubMed Web of Science ®Google Scholar
• Yamaleyeva LM, Chappell MC, Brosnihan KB, et al. Downregulation of apelin in the human placental chorionic villi from preeclamptic pregnancies. Am J Physiol Endocrinol Metab. 2015;309(10):E852–E60.
   PubMed Web of Science ®Google Scholar
• Van Mieghem T, Doherty A, Baczyk D, et al. Apelin in normal pregnancy and pregnancies complicated by placental insufficiency. Reprod Sci. 2016;23(8):1037–1043.
   PubMed Web of Science ®Google Scholar
• Yamaleyeva LM, Brosnihan KB, Elsangeedy E, et al. Systemic outcomes of (Pyr(1))-Apelin-13 infusion at mid-late pregnancy in a rat model with preeclamptic features. Sci Rep. 2019;9(1):8579.
   PubMedGoogle Scholar
• Dumic J, Dabelic S, Flögel M. Galectin-3: an open-ended story. Biochim Biophys Acta. 2006;1760(4):616–635.
   PubMed Web of Science ®Google Scholar
• Agnello L, Bivona G, Sasso BL, et al. Galectin-3 in acute coronary syndrome. Clin Biochem. 2017;50(1314):797–803.
   PubMedGoogle Scholar
• Gittens BR, Bodkin JV, Nourshargh S, Perretti M, Cooper D. Galectin-3: a positive regulator of leukocyte recruitment in the inflamed microcirculation. The Journal of Immunology 2017;198(11):4458-4469.
   Google Scholar
• Jeschke U, Mayr D, Schiessl B, et al. Expression of galectin-1,-3 (gal-1, gal-3) and the Thomsen–Friedenreich (TF) antigen in normal, IUGR, preeclamptic and HELLP placentas. Placenta. 2007;28(1112):1165–1173.
   PubMedGoogle Scholar
• Enninga EAL, Harrington SM, Creedon DJ, et al. Immune checkpoint molecules soluble program death ligand 1 and galectin‐9 are increased in pregnancy. Am J Reprod Immunol. 2018;79(2):e12795.
   PubMed Web of Science ®Google Scholar
• Menkhorst E, Koga K, Van Sinderen M, et al. Galectin-7 serum levels are altered prior to the onset of pre-eclampsia. Placenta. 2014;35(4):281–285.
   PubMed Web of Science ®Google Scholar
• Gao X, Balan V, Tai G, et al. Galectin-3 induces cell migration via a calcium-sensitive MAPK/ERK1/2 pathway. Oncotarget. 2014;5(8):2077.
   PubMedGoogle Scholar
• Kaufmann P, Black S, Huppertz B. Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol Reprod. 2003;69(1):1–7.
   PubMed Web of Science ®Google Scholar
• Idogun E, Imarengiaye C, Momoh S. Extracellular calcium and magnesium in preeclampsia and eclampsia. Afr J Reprod Health. 2007;11(2):89–94.
   PubMedGoogle Scholar
• Mahalle N, Naik SS, Kulkarni MV. Is hypomagnesaemia a coronary risk factor among Indians with coronary artery disease? J Cardiovasc Dis Res. 2012;3(4):280–286.
   PubMedGoogle Scholar
• Practice ACoO. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American college of obstetricians and gynecologists. Int J Gynaecol Obstet. 2002;77(1):67.
   PubMed Web of Science ®Google Scholar
• Al-Hakeim HK, Abdulzahra MS. Correlation between glycated hemoglobin and homa indices in Type 2 diabetes mellitus: prediction of beta-cell function from glycated hemoglobin/Korelacija Između Glikoliziranog Hemoglobina I Homa Indeksa U Dijabetes Melitusu Tipa 2: predviđanje Funkcije Beta Ćelija Na Osnovu Glikoliziranog Hemoglobina. J Med Biochem. 2015;34(2):191–199.
   PubMedGoogle Scholar
• Molvarec A, Prohászka Z, Nagy B, et al. Association of increased serum heat shock protein 70 and C-reactive protein concentrations and decreased serum α2-HS glycoprotein concentration with the syndrome of hemolysis, elevated liver enzymes, and low platelet count. J Reprod Immunol. 2007;73(2):172–179.
   PubMed Web of Science ®Google Scholar
• Group HSCR. Hyperglycaemia and adverse pregnancy outcome (HAPO) study: associations with maternal body mass index. BJOG. 2010;117(5):575–584.
   PubMed Web of Science ®Google Scholar
• Su Y-Y, Zhang J-Z, Wang F. Risk factors and adverse outcomes of preeclampsia: a tertiary care centrebased study in China. Biomed Res. 2017;28(3): 1262-1265.
   Google Scholar
• Lampinen KH, Rönnback M, Groop P-H, et al. A relationship between insulin sensitivity and vasodilation in women with a history of preeclamptic pregnancy. Hypertension. 2008;52(2):394–401.
   PubMed Web of Science ®Google Scholar
• Prieto M, Diez FM, Arevalo M, et al. PMC3668662. J Clin Invest. 2013;123(7):3124–3134.
   PubMedGoogle Scholar
• Beck P, Daughaday WH. Human placental lactogen: studies of its acute metabolic effects and disposition in normal man. J Clin Invest. 1967;46(1):103–110.
   PubMed Web of Science ®Google Scholar
• Wu P, Kwok CS, Haththotuwa R, et al. Pre-eclampsia is associated with a twofold increase in diabetes: a systematic review and meta-analysis. Diabetologia. 2016;59(12):2518–2526.
   PubMed Web of Science ®Google Scholar
• Rice MM, Landon MB, Varner MW, et al. Pregnancy-associated hypertension in glucose intolerant pregnancy and subsequent metabolic syndrome. Obstet Gynecol. 2016;127(4):771.
   PubMed Web of Science ®Google Scholar
• Timalsina S, Gyawali P, Bhattarai A. Comparison of lipid profile parameters and oxidized low-density lipoprotein between normal and preeclamptic pregnancies in a tertiary care hospital in Nepal. Int J Women’s Health. 2016;8:627.
   PubMed Web of Science ®Google Scholar
• El Khouly NI, Sanad ZF, Saleh SA, et al. Value of first-trimester serum lipid profile in early prediction of preeclampsia and its severity: A prospective cohort study. Hypertens Pregnancy. 2016;35(1):73–81.
   PubMed Web of Science ®Google Scholar
• Inuzuka H, Nishizawa H, Inagaki A, et al. Decreased expression of apelin in placentas from severe pre-eclampsia patients. Hypertens Pregnancy. 2013;32(4):410–421.
   PubMed Web of Science ®Google Scholar
• Al-Hakeim HK, Ali RAM. Proteinuria as the most relevant parameter affecting Fetuin-A levels in preeclampsia. Acta Facultatis Med Naissensis. 2015;32(4):267–277.
   Web of Science ®Google Scholar
• Aslan M, Celik O, Celik N, et al. Cord blood nesfatin-1 and apelin-36 levels in gestational diabetes mellitus. Endocrine. 2012;41(3):424–429.
   PubMed Web of Science ®Google Scholar
• Kourtis A, Gkiomisi A, Mouzaki M, et al. Apelin levels in normal pregnancy. Clin Endocrinol (Oxf). 2011;75(3):367–371.
   PubMed Web of Science ®Google Scholar
• Cobellis L, De Falco M, Mastrogiacomo A, et al. Modulation of apelin and APJ receptor in normal and preeclampsia-complicated placentas. Histol Histopathol. 2007;22(13):1–8.
   PubMedGoogle Scholar
• Suzuki S, Hiraizumi Y, Satomi M. History of abortion and perinatal outcomes associated with preeclampsia in nulliparous Japanese women. J Matern Fetal Neonatal Med. 2010;23(11):1318–1319.
   PubMed Web of Science ®Google Scholar
• Than A, Cheng Y, Foh L-C, et al. Apelin inhibits adipogenesis and lipolysis through distinct molecular pathways. Mol Cell Endocrinol. 2012;362(1):227–241.
   PubMed Web of Science ®Google Scholar
• Tribulatti MV, Figini MG, Carabelli J, Cattaneo V, Campetella O. Redundant and antagonistic functions of galectin-1,-3, and-8 in the elicitation of T cell responses.The Journal of Immunology 2012;188(7):2991-2999.
   Google Scholar
• Alves CM, Silva DA, Azzolini AEC, et al. Galectin-3 plays a modulatory role in the life span and activation of murine neutrophils during early Toxoplasma gondii infection. Immunobiology. 2010;215(6):475–485.
   PubMed Web of Science ®Google Scholar
• Blois SM, Barrientos G. Galectin signature in normal pregnancy and preeclampsia. J Reprod Immunol. 2014;101:127–134.
   PubMed Web of Science ®Google Scholar
• Venkatraman A, Hardas S, Patel N, et al. Galectin‐3: an emerging biomarker in stroke and cerebrovascular diseases. Eur J Neurol. 2018;25(2):238–246.
   PubMed Web of Science ®Google Scholar
• Pang J, Nguyen V, Rhodes D, et al. Relationship of galectin-3 with obesity, IL-6, and CRP in women. J Endocrinol Invest. 2016;39(12):1435–1443.
   PubMed Web of Science ®Google Scholar
• Riise HKR, Sulo G, Tell GS, et al. Incident coronary heart disease after preeclampsia: role of reduced fetal growth, preterm delivery, and parity. J Am Heart Assoc. 2017;6(3):e004158.
   PubMed Web of Science ®Google Scholar
• Abdellah A, Abdrabo A. Assessment of serum calcium, magnesium, copper and zinc levels in Sudanese pregnant women with preeclampsia. Glo Adv Res J Med Sci. 2014;3(2):33–36.
   Google Scholar
• Enaruna N, Ande A, Okpere E. Clinical significance of low serum magnesium in pregnant women attending the University of Benin Teaching Hospital. Niger J Clin Pract. 2013;16(4). DOI:10.4103/1119-3077.116887
   PubMed Web of Science ®Google Scholar
• Fawcett W, Haxby E, Male D. Magnesium: physiology and pharmacology. Br J Anaesth. 1999;83(2):302–320.
   PubMed Web of Science ®Google Scholar
• Li P, Liu S, Lu M, et al. Hematopoietic-derived galectin-3 causes cellular and systemic insulin resistance. Cell. 2016;167(4):973–84.e12.
   PubMed Web of Science ®Google Scholar
• Saksida T, Nikolic I, Vujicic M, et al. Galectin‐3 deficiency protects pancreatic islet cells from cytokine‐triggered apoptosis in vitro. J Cell Physiol. 2013;228(7):1568–1576.
   PubMed Web of Science ®Google Scholar
• Siwicki M, Engblom C, Pittet MJ. Gal3 links inflammation and insulin resistance. Cell Metab. 2016;24(5):655–656.
   PubMed Web of Science ®Google Scholar
• Ho JE, Liu C, Lyass A, et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol. 2012;60(14):1249–1256.
   PubMed Web of Science ®Google Scholar
• Nayor M, Wang N, Larson MG, et al. Circulating galectin‐3 is associated with cardiometabolic disease in the community. J Am Heart Assoc. 2015;5(1):e002347.
   PubMed Web of Science ®Google Scholar
• Schindler EI, Szymanski JJ, Hock KG, et al. Short-and long-term biologic variability of galectin-3 and other cardiac biomarkers in patients with stable heart failure and healthy adults. Clin Chem. 2016;62(2):360–366.
   PubMed Web of Science ®Google Scholar
• Medvedeva EA, Berezin II, Surkova EA, et al. Galectin-3 in patients with chronic heart failure: association with oxidative stress, inflammation, renal dysfunction and prognosis. Minerva Cardioangiol. 2016;64(6):595–602.
   PubMed Web of Science ®Google Scholar
• Jansen H, Koenig W, Jaensch A, et al. Prognostic utility of galectin-3 for recurrent cardiovascular events during long-term follow-up in patients with stable coronary heart disease: results of the KAROLA study. Clin Chem. 2016;62(10):1372–1379.
   PubMed Web of Science ®Google Scholar